厄贝沙坦对急性脑梗死患者血清超敏C反应蛋白水平的影响

目的 研究厄贝沙坦对急性脑梗死患者血清超敏C反应蛋白(hs-CRP)含量的影响.方法 将60例急性脑梗死患者随机分为厄贝沙坦组(30例)和常规治疗组(30例),并以30例非脑血管病患者作为对照组.厄贝沙坦组给予厄贝沙坦150 mg、阿司匹林100 mg,每天1次;常规治疗组给予阿司匹林100 mg,每天1次;两组其余治疗方法相同,连续治疗14 d.在治疗前、治疗14 d抽取静脉血,用比浊法检测血清hs-CRP含量,并评定神经功能缺损程度评分(NDS).结果 (1)两组脑梗死患者血清hs-CRP含量较对照组显著升高(均P＜0.01),血清hs-CRP含量与NDS呈正相关(r=0.34,P＜0.01).(2)厄贝沙坦组和常规治疗组治疗后血清hs-CRP含量和NDS较治疗前有显著降低(均P＜0.01).(3)厄贝沙坦组治疗前后血清hs-CRP含量的差值显著大于常规治疗组(P＜0.05).结论 厄贝沙坦能明显降低急性脑梗死患者的血清hs-CRP水平,并有助于脑梗死患者的神经功能恢复.

Effect of Irbesartan on the level of serum high-sensitivity C-reactive protein in patients with acute cerebral infarction

Objective To study the effect of Irbesartan on the level of serum high-sensitivity C-reactive protein(hs-CRP) in the patients with acute cerebral infarction(ACI).Methods 60 patients with ACI were randomly assigned to Irbesartan therapy group(n=30) treated with Irbesartan 150 mg/d combined Aspirin 100 mg/d and conventional therapy group(n=30) treated with Aspirin 100 mg/d.Both groups were treated for 14 consecutive days and the other measures of symptomatic therapy were same.And another 30 patients without cerebrovascular diseases were selected as control group.The levels of serum hs-CRP were measured and the scores of neurological deficit(NDS) were evaluated before and after treatment.Results(1) Before treatment the levels of serum hs-CRP of ACI patients in both therapy groups were significantly higher than that in control group(all P<0.01),and the level of serum hs-CRP was positively correlated with the NDS(r=0.34,P<0.01).(2) After treatment the levels of serum hs-CRP and NDS in both therapy groups were significantly lower than those before treatment(all P<0.01).(3) Deviation value of the serum hs-CRP between before and after treatment in Irbesartan therapy group was significantly higher than that in conventional therapy group(P<0.05).Conclusion Irbesartan can significantly decrease the level of hs-CRP and improve the neurological function in the patients with ACI.